NASDAQ:PCRX

Pacira Pharmaceuticals Stock Insider Trading

Healthcare > Drug Manufacturers - Specialty & Generic

Buy PCRX

*Your capital is at risk

$22.32

+0.0700 (+0.315%)

At Close: Jun 03, 2026

Pacira Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -2.60. In total, the insiders bought 2.16B and sold 25.9M PCRX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-2.60
● Buy	2.16B shares
● Sell	25.9M shares
63% Buy Activity Weak Negative Correlation
Buy Signal Low Confidence Feb 11, 2026 Analysis Breakdown: Weakened by a contradictory negative Insider Power Score. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 30, 2026 Sell	Common Stock F-InKind	Teehan Brendan Chief Commercial Officer	Officer	5 182 Value: $106.4K
Jan 27, 2026 Buy	Stock Option (Right to Buy) A-Award	Hirawat Samit Director	Director	39 291 Value: $779.9K
Jan 27, 2026 Buy	Common Stock J-Other	Hirawat Samit	Director	0 Value: $0
Jan 05, 2026 Sell	Common Stock S-Sale	Riker Lauren Senior Vice President, Finance	CEO / President	1 416 Value: $34.3K
Jan 02, 2026 Sell	Common Stock F-InKind	Lee Frank D. Chief Executive Officer	CEO / President	9 272 Value: $226.8K
Jan 02, 2026 Sell	Common Stock F-InKind	Riker Lauren Senior Vice President, Finance	CEO / President	159 Value: $4K
Jan 02, 2026 Sell	Common Stock F-InKind	Slonin Jonathan Chief Medical Officer	Officer	381 Value: $9K
Dec 31, 2025 Buy	Common Stock A-Award	Teehan Brendan Chief Commercial Officer	Officer	402 Value: $4K
Dec 10, 2025 Buy	Common Stock M-Exempt	Cross Shawn Chief Financial Officer	C-Suite Officer	9 104 Value: $149.8K
Dec 10, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Cross Shawn Chief Financial Officer	C-Suite Officer	9 104 Value: $149.8K
Dec 10, 2025 Sell	Common Stock S-Sale	Cross Shawn Chief Financial Officer	C-Suite Officer	9 104 Value: $228.9K
Dec 09, 2025 Buy	Common Stock M-Exempt	Cross Shawn Chief Financial Officer	C-Suite Officer	15 896 Value: $261.5K
Dec 09, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Cross Shawn Chief Financial Officer	C-Suite Officer	15 896 Value: $261.5K
Dec 09, 2025 Sell	Common Stock S-Sale	Cross Shawn Chief Financial Officer	C-Suite Officer	15 896 Value: $397.9K
Nov 17, 2025 Sell	Common Stock S-Sale	Slonin Jonathan Chief Medical Officer	Officer	3 960 Value: $95.4K
Nov 10, 2025 Sell	Common Stock S-Sale	Cross Shawn Chief Financial Officer	C-Suite Officer	12 060 Value: $266.4K
Oct 31, 2025 Sell	Common Stock F-InKind	Cross Shawn Chief Financial Officer	C-Suite Officer	6 690 Value: $143.0K
Sep 04, 2025 Sell	Common Stock S-Sale	Ceesay Abraham Director	Director	2 354 Value: $64.0K
Sep 04, 2025 Sell	Common Stock S-Sale	Ceesay Abraham Director	Director	2 354 Value: $64.0K
Aug 07, 2025 Sell	Common Stock S-Sale	Bigal Marcelo Director	Director	4 912 Value: $116.3K
Aug 07, 2025 Sell	Common Stock S-Sale	Bigal Marcelo Director	Director	4 912 Value: $116.3K
Aug 01, 2025 Sell	Common Stock F-InKind	Slonin Jonathan Chief Medical Officer	Officer	315 Value: $7K
Aug 01, 2025 Sell	Common Stock F-InKind	Slonin Jonathan Chief Medical Officer	Officer	315 Value: $7K
Jun 11, 2025 Buy	Common Stock A-Award	Kronenfeld Mark A. Director	Director	6 163 Value: $150.0K
Jun 11, 2025 Buy	Common Stock A-Award	Kronenfeld Mark A. Director	Director	9 999 Value: $243.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PACIRA PHARMACEUTICALS

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted ner...

Read Full Profile Here